# QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Source: https://onco.cc/trials/nct03228667/  
OnCo record `nct03228667` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nogapendekin alfa inbakicept, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by ImmunityBio, Inc., active and no longer recruiting.

## Summary

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors is a phase 2 interventional study registered as NCT03228667 by ImmunityBio, Inc., with 40 participants planned, started 2018-12-11 and due to reach its primary completion in 2029-08-31. Interventions recorded: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab. Conditions listed: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03228667
- Phase: 2
- Setting: QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Sponsor: ImmunityBio, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT03228667: https://clinicaltrials.gov/study/NCT03228667

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Avelumab](https://onco.cc/drugs/avelumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct03228667.json